Outset Medical, Inc.
Close on Oct 19, 2026
- Market cap
- $70.75K
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 9, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | After market close | $31.60M | $-0.97 | $-0.80 |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | After market close | $27.90M | $-1.03 | $-0.83 |
| Q4 FY2025 Ended Dec 31, 2025 | Jan 12, 2026 | Before market open | $28.90M | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 10, 2025 | After market close | $29.40M | $-1.00 | $-0.69 |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 6, 2025 | After market close | $31.40M | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 7, 2025 | After market close | $29.80M | $-3.66 | $-3.24 |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 19, 2025 | After market close | $29.50M | $-0.49 | $-0.37 |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 6, 2024 | After market close | $28.70M | $-0.55 | $-0.39 |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 7, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 8, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Jan 8, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Aug 6, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| revenue increase | 2026 | 5% to 9% growth | Maintained |
| revenue | 2026 | $125.00M to $130.00M | Maintained |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Outset Medical filed with the SEC
Outset Medical Reports Second Quarter 2026 Results
Results of operations · EX-99.1 to Form 8-K
Outset Medical Reports First-Quarter Results
Results of operations · EX-99.1 to Form 8-K
Outset Medical Reports Fourth Quarter and Full Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Next-Generation Tablo Hemodialysis System Receives FDA Clearance,
Other events · EX-99.1 to Form 8-K
Outset Medical Reports Unaudited Fourth Quarter and 2025 Results
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Outset Medical Investor Presentation 2026
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
Outset Medical Reports Third-Quarter Results
Results of operations · EX-99.1 to Form 8-K
Outset Medical Second-Quarter Results Demonstrate Continued Momentum, Punctuated by Strong Revenue Growth, Console Placements and Utilization
Results of operations · EX-99.1 to Form 8-K
Outset Medical Appoints Renee Gaeta as Chief Financial Officer
Executive or director change · Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
Outset Medical Appoints Industry Veteran Kevin O’Boyle
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Outset Medical First-Quarter Results Demonstrate Strong Growth in Console and Recurring Revenue as Gross Margin Expanded and Cash Use Declined
Results of operations · EX-99.1 to Form 8-K
Reports of Independent Registered Public Accounting Firm
Listing notice · Other events · EX-99.1 to Form 8-K
Outset Medical Reports Fourth Quarter and Full Year 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Outset Medical Announces $169 Million Private Placement Financing From Leading Mutual Funds and
Material agreement · Results of operations · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Outset Medical Reports Third Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Outset Medical Reports Second Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Outset Medical Reports First Quarter 2024 Financial Results
Results of operations · Executive or director change · Other events · EX-99.1 to Form 8-K
Outset Medical's TabloCart with Prefiltration Receives FDA 510(k) Clearance
Other events · EX-99.1 to Form 8-K
Outset Medical Announces Appointment of Medical Technology Veteran Brent D. Lang to its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Outset Medical Reports Fourth Quarter and Full Year 2023 Financial Results
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Outset Medical Reports Unaudited Fourth Quarter and 2023 Revenue, Provides 2024 Revenue and non-GAAP Gross Margin Guidance
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Outset Medical Investor Presentation January 2024
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Outset Medical Reports Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Outset Medical Investor Presentation November 2023
Results of operations · EX-99.2 to Form 8-K
Outset Medical Reports Preliminary Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Outset Medical Reports Second Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Outset Medical Reports First Quarter 2023 Financial Results
Results of operations · EX-99 to Form 8-K
Outset Medical Reports Fourth Quarter and Full Year 2022 Financial Results
Results of operations · Executive or director change · EX-99 to Form 8-K
Outset Medical Reports Expected Fourth Quarter and Full Year 2022 Revenue, Provides 2023 Revenue and non-GAAP Gross Margin Guidance
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Outset Medical Investor Presentation January 2023
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Outset Medical Reports Third Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Outset Medical Secures Up To $300 Million in Debt Financing
Material agreement · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
Outset Medical Resumes Shipment of Tablo Systems for Home Use,
Results of operations · Other events · EX-99.1 to Form 8-K
Outset Medical Announces Shipment Hold on New Tablo Systems for Home Use Pending FDA Review and Clearance of Recent 510(K) Submission
Results of operations · Other events · EX-99.1 to Form 8-K
Outset Medical Reports First Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Outset Medical Names Business Leader Dale E. Jones to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Outset Medical Reports Fourth Quarter and Full Year 2021 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Outset Medical Investor Presentation February 2022 Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Outset Medical Reports Third Quarter 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K